<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Adenoviruses have been proposed as potential vectors for gene therapy in the central <z:mp ids='MP_0008912'>nervous</z:mp> system, but there are no reports of their use in the treatment of a <z:e sem="disease" ids="C0006111" disease_type="Disease or Syndrome" abbrv="">brain disease</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Because central administration of interleukin-1 receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi> protein (IL-1ra) reduces ischemic brain damage, we determined whether a recombinant adenovirus vector carrying the human IL-1ra cDNA (Ad.RSVIL-1ra) could be used to ameliorate brain injury in permanent focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Groups of six rats received intraventricular injections of Ad.RSVIL-1ra or a control adenovirus containing the Escherichia coli beta-galactosidase gene (Ad.RSVlacZ) </plain></SENT>
<SENT sid="3" pm="."><plain>Histochemical staining for beta-galactosidase 5 days after virus injection indicated that transgene expression was confined primarily to the cells lining the ventricle </plain></SENT>
<SENT sid="4" pm="."><plain>The concentrations of IL-1ra injected animals, achieving levels of 9.1 +/- 3.3 ng/g in brain and 23.7 +/- 22.5 ng/ml in CSF </plain></SENT>
<SENT sid="5" pm="."><plain>In these animals, cerebral <z:mpath ids='MPATH_124'>infarct</z:mpath> volume resulting from 24 h of permanent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> was reduced 64% </plain></SENT>
<SENT sid="6" pm="."><plain>These studies demonstrate that adenoviral vectors can be used to deliver genes that attenuate brain injury </plain></SENT>
</text></document>